Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells

DSpace/Manakin Repository

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells

Citable link to this page

 

 
Title: Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
Author: Vujic, Igor; Sanlorenzo, Martina; Esteve-Puig, Rosaura; Vujic, Marin; Kwong, Andrew; Tsumura, Aaron; Murphy, Ryan; Moy, Adrian; Posch, Christian; Monshi, Babak; Rappersberger, Klemens; Ortiz-Urda, Susana

Note: Order does not necessarily reflect citation order of authors.

Citation: Vujic, I., M. Sanlorenzo, R. Esteve-Puig, M. Vujic, A. Kwong, A. Tsumura, R. Murphy, et al. 2016. “Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.” Oncotarget 7 (6): 7297-7306. doi:10.18632/oncotarget.6907. http://dx.doi.org/10.18632/oncotarget.6907.
Full Text & Related Files:
Abstract: Oncogenic NRAS mutations are frequent in melanoma and lead to increased downstream signaling and uncontrolled cell proliferation. Since the direct inhibition of NRAS is not possible yet, modulators of NRAS posttranslational modifications have become an area of interest. Specifically, interfering with NRAS posttranslational palmitoylation/depalmitoylation cycle could disturb proper NRAS localization, and therefore decrease cell proliferation and downstream signaling. Here, we investigate the expression and function of NRAS depalmitoylating acyl protein thioesterases 1 and 2 (APT-1, APT-2) in a panel of NRAS mutant melanoma cells. First, we show that all melanoma cell lines examined express APT-1 and APT-2. Next, we show that siRNA mediated APT-1 and APT-2 knock down and that the specific APT-1 and -2 inhibitors ML348 and ML349 have no biologically significant effects in NRAS mutant melanoma cells. Finally, we test the dual APT-1 and APT-2 inhibitor palmostatin B and conclude that palmostatin B has effects on NRAS downstream signaling and cell viability in NRAS mutant melanoma cells, offering an interesting starting point for future studies.
Published Version: doi:10.18632/oncotarget.6907
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872786/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320333
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters